Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to approve pharmaceutical plants in the country will significantly change timelines for the pharma industry.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance for the year. For the full year, the company now expects sales growth between 13% and 21%.